To identify the effect of HER-2 and PNP inhibition on the viability of HER2-positive BC cells, SKBR3 cells were treated with trastuzumab (10 μg/mL), BCX-1777 (10 μM), or a combination of trastuzumab and BCX-1777. The gene discussed is ERBB2; the disease is breast cancer.